Stock ROIV ROIVANT SCIENCES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
10.36 USD -0.29% Intraday chart for Roivant Sciences Ltd. -5.65% -7.75%
May. 30 Transcript : Roivant Sciences Ltd., Q4 2024 Earnings Call, May 30, 2024
May. 30 Roivant Sciences' Fiscal Q4 Net Loss Widens, Revenue Rises MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ROIVANT SCIENCES LTD. Stock Roivant Sciences Ltd.
-7.75% 7.65B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
B+
NOVARTIS AG Stock Novartis AG
+9.78% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
A+
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ROIV Stock
  4. Ratings Roivant Sciences Ltd.